IP Library Granted Patent US 7,150,971
Granted Patent B2
US 7,150,971 · App. 10/153,398 · Granted Dec 19, 2006

Membrane-resident steroid receptors and methods of use thereof

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,150,971
App. No.
10/153,398
Granted
Dec 19, 2006
Kind
B2
Abstract

This invention pertains to the discovery that DPR-1 encodes a putative nuclear hormone receptor (NHR) that, based on gene reporter studies, is expressed in the endoderm throughout the life of the worm. NHR family members are transcriptional regulators that are activated when bound to their small lipophilic ligands such as steroids. While some NHRs are localized to the nucleus, others are cytoplasmic in the absence of ligand and translocate to the nucleus upon ligand binding. Once in the nucleus, they bind target sequences and regulate gene expression.

Claims (40)

1. A method of screening for an agent that modulates dauer formation by a nematode, said method comprising: contacting a nematode with a test agent; and detecting a change in localization of a nuclear hormone receptor, said nuclear hormone receptor characterized by a DNA binding domain and a corresponding ligand binding domain as set forth in an amino acid selected form the group consisting of

DPR-1 polypeptide of SEQ ID NO:15; or

C54C8 comprising SEQ ID NOs:2 and 9; or

Y38E10 comprising SEQ ID NOs:3 and 10

wherein a change in localization indicates that said test agent is a good candidate agent modulating dauer formation by a nematode.

2. The method of claim 1 , wherein said change in localization is a change from localization in the cell nucleus to localization in the cell membrane.

3. The method of claim 1 , wherein said change in localization is detected by labeling said nuclear receptor hormone.

4. The method of claim 1 wherein said nuclear hormone receptor is DPR-1.

5. A method for identifying a compound which binds to a DPR-1 nuclear hormone receptor which can locate to a plasma membrane, the method including:

a. bringing into contact

(i) a nuclear hormone receptor polypeptide having a DNA binding domain and a corresponding ligand binding domain, said polypeptide having a sequence selected for the group consisting of

DPR-1 polypeptide of SEQ ID NO:15; or

C54C8 comprising SEQ ID NOs:2 and 9; or

Y38E10 comprising SEQ ID NOs:3 and 10

With

(ii) a test compound, under conditions wherein said nuclear hormone receptor polypeptide and said test compound will bind; and

b. determining binding between said nuclear hormone receptor polypeptide and said test compound.

6. The method of claim 5 wherein said DPR-1 polypeptide is expressed in a cell and located on a cell membrane.

7. The method of claim 5 wherein said DPR-1 polypeptide is a polypeptide of SEQ ID NO:15.

8. The method of claim 5 wherein said DPR-1 polypeptide is expressed in a cell by a transgene coding for said DPR-1 polypeptide.

9. The method of claim 5 wherein said transgene comprises a sequence of SEQ ID NO: 16.

10. The method of claim 5 wherein said determining step comprises a method selected from the group consisting of capillary electrophoresis, a Western blot, mass spectroscopy, ELISA, immunochromatography, and immunohistochemistry.

11. A method for identifying a compound which binds to a DPR-1 nuclear hormone receptor which can locate to a plasma membrane, the method including:

a. bringing into contact

(i) a cell expressing a nuclear hormone receptor polypeptide having a DNA binding domain and a corresponding ligand binding domain, said polypeptide having a sequence selected for the group consisting of:

DPR-1 polypeptide of SEQ ID NO:15; or

C54C8 comprising SEQ ID NOs:2 and 9; or

Y38E10 comprising SEQ ID NOs:3 and 10; with

(ii) a test compound, under conditions wherein said DPR-1 nuclear hormone receptor and said test compound will bind; and

b. determining binding between said nuclear hormone receptor polypeptide and said test compound.

12. The method of claim 11 wherein said cell is a C. elegans cell.

13. The method of claim 12 wherein the cell is in a C. elegans animal.

14. The method of claim 11 wherein said cell is an oocyte.

15. The method of claim 11 wherein said cell is cultured ex vivo.

16. The method of claim 12 wherein step a (ii) further comprises the step of contacting the cell with dauer pheromone.

17. The method of claim 11 wherein said DPR-1 polypeptide is a polypeptide of SEQ ID NO:15.

18. The method of claim 11 wherein said cell expresses a transgene encoding said nuclear hormone receptor.

19. The method of claim 18 wherein said transgene is linked to a reporter gene.

20. The method of claim 11 wherein said determining step comprises a method selected from the group consisting of a Northern blot, a Southern blot using DNA derived from an DPR-1 RNA, an array hybridization, an affinity chromatography, and an in situ hybridization.

21. The method of claim 11 wherein said test compound is a nucleic acid.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 25, 2010
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024135/0059 →
CONFIRMATORY LICENSE Recorded Apr 16, 2008
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020812/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2002
From: ROTHMAN, JOEL H.; NEWMAN-SMTIH, ERIN; BROITMAN-MADURO, GINA
To: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Reel/Frame 013459/0645 →
Continuity (2)
Provisional Application 6029255300 · May 21, 2001
Related Publication 20030108987A1 · Jun 12, 2003